
Stevanato Group
INNOVATION
ROADSHOW
April 22, 2026
Hyderabad, India

Stevanato Group

# INNOVATION ROADSHOW

22 April 2026
Hyderabad, India

**CONTENTS**


Conference Agenda ..... 3

Meet Our Presenters ..... 4-13

Stevanato Group

# INNOVATION ROADSHOW

April 22, 2026
Hyderabad, India

## CONFERENCE AGENDA

| | |
|---|---|
| **13:45-14:15** | **Registrations** |
| **14:15-14:25** | **Welcome and Introduction**<br>Alessandro Orlando, Senior Director, Regional Business Indo-Pacific, Stevanato Group |
| **14:25-14:40** | **Navigating the Future of Pharma: Outlook and Major Trends in the End-Market and Primary Packaging**<br>Aditi Jain, Principal, Management Consulting, South Asia, IQVIA |
| **14:40-15:00** | **Accelerating Speed-to-Market Through Strategic Supplier Synergy**<br>Mr. Dhawal Upadhyay, Head - Program Management (GMP & Late-stage programs)<br>Intas Pharmaceuticals Ltd (Biopharma Division) |
| | **I SESSION: DRUG PRODUCT & DEVICE INTERACTION** |
| **15:00-15:15** | **How RTU Vials and Cartridges Can Be a Suitable, Cost-effective Way to Meet GMP Annex 1 Requirements**<br>Valerio Ravazzolo, Product Management Cartridges Platform, Stevanato Group |
| **15:15-15:30** | **Compatibility of RTU Cartridges with GLP-1 Drugs and Devices**<br>Valerio Ravazzolo, Product Management Cartridges Platform, Stevanato Group |
| **15:30-15:50** | **De-risking Combination Product Development: Integration of Aidaptus® Autoinjector with High-performance Alba® Prefillable Syringe**<br>Siva Prasad Reddy,Technical Business Development Manager, Owen Mumford, United Kingdom.<br>Hari Rachamala, TAM Manager APAC, Stevanato Group |
| **15:50-16:05** | **Case Study: Long-Term Placebo Stability with Polysorbate 80 in Silicone-Oil Glass PFS and Risk Mitigation Strategies**<br>Daniel Martinez, Senior Director, Product Management – DCS, Stevanato Group |
| **16:05-16:10** | **Q&A**<br>Vinayak Joshi, Country Manager, Stevanato Group |
| **16:10-16:30** | **Coffee/Tea Break** |
| **16:30-16:45** | **Connecting your Molecule to the Global Market with Analytical & Testing Services**<br>Mattia Griso, Business Development and Proposal Manager – TEC, Stevanato Group |
| **16:45-17:05** | **Current Extractable & Leachables Considerations for Small Volume Parenterals**<br>Dr. Sona Kovackova, Senior E&L Expert, Nelson Labs |
| | **II SESSION: SUPPLY CHAIN PERFORMANCES** |
| **17:05-17:20** | **Visual inspection technologies applied to injectables: focus on GLP-1 and mAbs products**<br>Gaetano Baccinelli, Account Manager, Stevanato Group |
| **17:20-17:30** | **Presenting our Excellence Hub in the U.S.**<br>Daniel Martinez, Senior Director, Product Management – DCS, Stevanato Group |
| **17:30-17:40** | **Q&A & Conclusions**<br>Vinayak Joshi, Country Manager, Stevanato Group |
| **17:40-18:45** | **Dinner Networking Reception** |

# Alessandro Orlando

Senior Director, Regional Business Indo-Pacific,
Stevanato Group

With a Master of Economics at the University of Pavia and an EMBA at Rutgers University (New Jersey), Alessandro Orlando has developed many skills and knowledge during his academics and professional career.
He joined Stevanato Group in May 2017 as the Head of Sales activities for the Asia Pacific Region, bringing a deep experience of this market; indeed, he had previously worked at Sipa S.p.A as Sales & Marketing Director-China, spending seven years in China and covering here managerial positions in three different companies.
Thanks to his contribution, Stevanato Group is expanding its business in the Asia Pacific Region, exploiting the many insights Alessandro has acquired during his previous working experiences.

**WELCOME AND INTRODUCTION**

# Aditi Jain

Principal, Management Consulting, South Asia,
IQVIA

Aditi is a seasoned consulting leader recognized for driving measurable business impact across global life sciences organizations. Known for her strategic insight, analytical rigor, and relentless execution, she has advised top global and Indian pharmaceutical, API, CRDMO companies in the areas of portfolio prioritization, opportunity assessment, go to market strategy, amongst others. Partnering closely with her clients' senior management and commercial leaders, Aditi has helped strengthen their internal functions, enhance decision making, and deliver improved business performance.
Aditi holds an MBA degree from the Indian Institute of Management Bangalore, India and a Bachelor of Engineering degree from Punjab Engineering College, Chandigarh, India where she graduated at the top of her class.

## NAVIGATING THE FUTURE OF PHARMA: OUTLOOK AND MAJOR TRENDS IN THE END-MARKET AND PRIMARY PACKAGING

The speech outlines key trends shaping the global biopharmaceutical landscape through 2030, with a focus on biologics and vaccines. It highlights the rapid growth of GLP-1 therapies, the resurgence of mRNA vaccines, and the evolving role (in terms of future adoption in different pharmaceutical segments) of Drug Containment and Delivery Systems.

# Dhawal Upadhyay

Program Management (GMP & Late-stage programs)
Intas Pharmaceuticals Ltd (Biopharma Division)

PMP® Certified, Global Program manager with 16+ years of experience spanning Program management, GMP and technical operation within the Biopharma and Pharma industry.

## ACCELERATING SPEED-TO-MARKET THROUGH STRATEGIC SUPPLIER SYNERGY

As drug molecules become more complex, the siloed approach to development and containment is no longer viable. This session explores how Senior Project Managers can transition from 'managing vendors' to 'orchestrating ecosystems.' We will dive into discussion where early integration of delivery system expertise—specifically in high-value biologics—reduced regulatory hurdles and time to market.

# Valerio Ravazzolo

Product Management Cartridges Platform,
Stevanato Group

Valerio Ravazzolo is Product Manager for the Cartridge Platform within the DCS Business Unit at Stevanato Group, where he focuses on the evolution of cartridge solutions from both a technical and market perspective.
He joined Stevanato Group in 2015, starting in Quality Assurance and later moving into a Technical Account Manager role. In this position, he supported key customers and gradually expanded his scope of responsibility.
Today, as Product Manager, he brings together this experience to support product strategy, development, and long-term platform growth.
Valerio holds a master's degree in mechanical engineering from the University of Padua.

## HOW RTU VIALS AND CARTRIDGES CAN BE A SUITABLE, COST-EFFECTIVE WAY TO MEET GMP ANNEX 1 REQUIREMENTS

Ready-to-Use (RTU) vials and cartridges as suitable, time-efficient and cost-effective answer to regulation requirements
The current EU GMP Annex 1 emphasizes the importance of handling critical manufacturing steps and managing risks associated with contamination. It is crucial for pharmaceutical companies to align their quality management system and establish appropriate Contamination Control Strategy (CCS) and Quality Risk Management (QRM).
By choosing Ready-To-Use (RTU) containers, pharma companies can remove critical operating units and significantly automate their manufacturing process and reduce human intervention, minimizing potential risks of contamination connected to the washing and depyrogenation phases, making operations leaner, and allowing pharmaceutical companies to focus on key activities with the most added value.

## COMPATIBILITY OF RTU CARTRIDGES WITH GLP-1 DRUGS AND DEVICES

The rapid growth of GLP-1–based therapies for diabetes and obesity is reshaping requirements for primary packaging, filling operations, and drug–device compatibility. As multidose pen injectors emerge as the preferred delivery system, cartridges must ensure consistent performance, drug stability, and operational efficiency at an industrial scale. This presentation explores the role of ready-to-use (RTU) glass cartridges in supporting GLP-1 applications, focusing on container compatibility, silicone behavior, particle release, and extractables. Using a six-month stability and performance study conducted with a representative semaglutide formulation, the presentation demonstrates how an optimized RTU platform can reduce complexity, lower TCO, and accelerate time to market while meeting stringent quality and regulatory expectations.

# Siva Prasad Reddy

Siva Prasad Reddy,Technical Business Development Manager,
Owen Mumford, United Kingdom.

Siva is a strategic leader with over 2 decades of experience in combination product development and advanced drug delivery systems. As Technical BDM for Global Platform Autoinjectors at Owen Mumford, UK, he is responsible for new business partnerships, technical roadmap, and cross-functional execution of next-generation delivery platforms and bespoke developments to enhance patient outcomes and accelerate market readiness.
Recognized as a solution provider with a strong understanding of the drug–device interface, Siva has successfully guided complex programs from concept through commercialization — ensuring technical robustness, regulatory compliance, and user-centric design. Prior to Owen Mumford, he held various roles at Stevanato Group, Becton Dickinson, and West Pharmaceutical Services, driving integrated development and lifecycle management for global combination product portfolios.
Siva continues to champion collaboration between science, engineering, and regulatory disciplines to deliver innovative and compliant drug delivery solutions.

# Hari Rachamala

TAM Manager APAC, Stevanato Group

Hari Rachamala brings almost 15 years of experience in the packaging industry, with 7 years focused on pharmaceutical packaging. As a Technical Account Manager in Stevanato Group, he plays a pivotal role in Spearheading pre-sales technical support for new projects, providing comprehensive customer support throughout the partnership, addressing non-compliant product issues, and supporting technical studies and audits. He leads a team of technical experts dedicated to supporting customers in their drug delivery challenges.

## DE-RISKING COMBINATION PRODUCT DEVELOPMENT: INTEGRATION OF AIDAPTUS® AUTOINJECTOR WITH HIGH-PERFORMANCE ALBA® PREFILLABLE SYRINGE

The Aidaptus® autoinjector and Alba® & Nexa® syringes are advanced, flexible platforms designed to meet the increasing demand for subcutaneous delivery of high value injectables.
Autoinjector-syringe compatibility is critical to the success of the combination product. To ensure reliable and scalable products, Owen Mumford's and Stevanato Group's internal test houses continuously investigate functional performances across varying conditions and characterize critical syringe attributes such as break loose and glide forces under stress conditions. This presentation will demonstrate the importance of this rigorous testing program and the importance of designing with integration from the beginning, in order to ensure combination product performance in real-use scenarios, supporting the accelerated development of biologics and other advanced therapies.

# Daniel Martinez

Senior Director, Product Management – DCS,
Stevanato Group

Daniel Martinez is the Sr Director of Product Management for DCS at Stevanato Group.
In his role, he is responsible for the development and deployment of the go-to-market strategy and product positioning of drug containment solutions.
He has over 16 years experience in the sector in different functions such as production, technical/quality liaison, quality, project management, and sales.
He holds a bachelor's degree in Mechatronics Engineering from the Instituto Tecnológico y de Estudios Superiores de Monterrey.
Before joining Stevanato Group, Mr. Martinez covered commercial and operational roles in international companies dedicated to primary packaging.

## CASE STUDY: LONG-TERM PLACEBO STABILITY WITH POLYSORBATE 80 IN SILICONE-OIL GLASS PFS AND RISK MITIGATION STRATEGIES

This case study investigates the long-term stability of prefilled glass syringes with varying siliconization levels and stopper types, evaluated in both 1 mL long and 2.25 mL formats. A placebo solution containing polysorbate 80 was used for filling. Conducted collaboratively by Coriolis Pharma and Stevanato Group over a 21-month stability period, the study assessed subvisible particles (SbVP) and key mechanical performance parameters—including Break Loose and Extrusion Forces—across both syringe formats. The results offer insights to support the selection of syringe configurations optimized for biologics, as well as risk mitigation strategies during drug development.

# Mattia Griso

Business Development and Proposal Manager – TEC,
Stevanato Group

Business development and analytical service manager, with six years of experience at Stevanato Group's Technology Excellence Center. Strong background in pharmaceutical and medical device development, specialized in analytical expertise and development projects supporting clinicalphase solutions.

## CONNECTING YOUR MOLECULE TO THE GLOBAL MARKET WITH ANALYTICAL & TESTING SERVICES

Bringing a molecule from development to the global market requires more than robust manufacturing - it demands a deep understanding of how the drug product interacts with its container, delivery system, and realworld conditions across its lifecycle. Technology Excellence Centers (TECs) provide independent, sciencedriven analytical and testing services designed to derisk critical decisions from early development through commercialization.
Integrated analytical capabilities, spanning material characterization, drugcontainer interaction, performance testing, and NFHU fill & finish, support informed product selection, design verification, and lifecycle management. By combining advanced testing expertise with a strong quality framework and direct collaboration with customers, TECs act as a strategic bridge between molecule development and global market readiness. This holistic analytical approach can accelerate development timelines, support regulatory expectations, and enable confident scaleup and commercialization.

# Dr. Sona Kovackova

Senior E&L Expert,
Nelson Labs

Sona Kovackova earned her PhD in Organic Chemistry from the University of Chemistry and Technology in Prague, Czech Republic. She began her career as a Scientist at the Rega Institute for Medical Research, KU Leuven, Belgium, and later transitioned to Quality Control of medicines at the Belgian Institute of Public Health.
In 2017, Sona joined Nelson Labs Europe where she specializes in Extractables & Leachables studies, leveraging her extensive background in both analytical and organic chemistry. Sona's primary focus lies in injectable applications, where understanding the interaction between drug products and their primary packaging is critical.

## CURRENT EXTRACTABLE & LEACHABLES CONSIDERATIONS FOR SMALL VOLUME PARENTERALS

sThe presentation will give introduction to Extractables and Leachables (E&L) for parenteral drug products and will highlight the key factors that contribute to the success of E&L projects. When making parenteral drug products, pharmaceutical companies are faced with the regulatory requirements to further investigate the materials that will be in contact with the drug product either during manufacturing, intermediate storage, storage in its final packaging, or during the delivery of the drug to the patient. Over the past few decades, the scrutiny applied by EMEA and FDA regulators to E&L data has significantly increased. Understanding what regulators expect is crucial, as is aligning the design of an E&L study to meet these expectations.

# Gaetano Baccinelli

Account Manager,
Stevanato Group

Gaetano Baccinelli is an Account Manager of Stevanato Group, specializing in manufacturing inspection machines for parenteral products.
From 1992 to 1999, he spent seven years working in the USA branch of a renowned Italian group recognized worldwide as a skilled engineer in the After Sales Department.
He worked as manager of the After Sales and Service Department and as Area Sales Manager for leading inspection systems companies, following Japan and USA market.
Mr. Baccinelli has brought into Stevanato Group a deep knowledge and qualified skills, strongly contributing to the improvement of the Group.

## VISUAL INSPECTION TECHNOLOGIES APPLIED TO INJECTABLES: FOCUS ON GLP-1 AND MABS PRODUCTS

This presentation will provide an overview of inspection technologies for parenteral injectable products, presenting special tools developed for particle detection in mAbs products, liquids, and freeze-dried products. We will also present the latest developments for cartridge inspection in the GLP-1 therapeutic area, aiming to grant process stability with a high detection rate and a minimum false rejection rate

# Daniel Martinez

Senior Director, Product Management – DCS,
Stevanato Group

Daniel Martinez is the Sr Director of Product Management for DCS at Stevanato Group.
In his role, he is responsible for the development and deployment of the go-to-market strategy and product positioning of drug containment solutions.
He has over 16 years experience in the sector in different functions such as production, technical/quality liaison, quality, project management, and sales.
He holds a bachelor's degree in Mechatronics Engineering from the Instituto Tecnológico y de Estudios Superiores de Monterrey.
Before joining Stevanato Group, Mr. Martinez covered commercial and operational roles in international companies dedicated to primary packaging.

**PRESENTING OUR EXCELLENCE HUB IN THE U.S.**

Stevanato Group's Fishers site is a purpose-built U.S. excellence hub designed to support pharmaceutical and biotech companies with integrated, domestic capabilities across the drug life cycle. Combining high-volume production of EZ-fill® ready-to-use vials and syringes, advanced drug delivery device manufacturing, and local after-sales support, the site enables faster time-to-market and supply chain derisking. This session highlights how the Fishers site addresses the growing demand for biologics, GLP-1 therapies, vaccines, and self-administration trends, delivering consistent quality, flexibility, and innovation for the U.S. and global markets.

Stevanato Group

# INNOVATION ROADSHOW

**22 April 2026**
**Hyderabad, India**

**AVASA HOTEL**
Plot No: 15,24,25 & 26
Sector - 1,
Survey No: 64, Huda Techno Enclave, Madhapur,
Hyderabad- 500081

**22 April 2026**
13:45 – 18:45

stevanatogroup.com